ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).

被引：0
|
作者：
Ma, Fei
Qiu, Fuming
Tong, Zhongsheng
Shi, Yehui
Yu, Guohua
Wu, Xinhong
Wang, Hong
Wang, Jiani
Yang, Hua
Liu, Anwen
Zhang, Yan
Zheng, Hongmei
Lan, Qiongyu
Zhang, Yongqiang
Cheng, Ying
Zhou, Qing
Xing, Xiaoyan
Chen, Xiaomei
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[5] Weifang Med Univ, Weifang Peoples Hosp, Weifang, Peoples R China
[6] Weifang Med Univ, Affiliated Hosp 1, Weifang, Peoples R China
[7] Huazhong Univ Sci & Technol, Tongji Med Coll, Hubei Canc Hosp, Dept Breast Surg, Wuhan, Peoples R China
[8] Hubei Prov Clin Res Ctr Breast Canc, Wuhan, Peoples R China
[9] Wuhan Clin Res Ctr Breast Canc, Wuhan, Peoples R China
[10] Nanchang Third Hosp, Nanchang, Jiangxi, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[12] Affiliated Hosp Hebei Univ, Baoding, Hebei, Peoples R China
[13] Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[14] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[15] Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Jiangxi, Peoples R China
[16] Beijing Hosp, Beijing, Peoples R China
[17] Jilin Canc Hosp, Changchun, Peoples R China
[18] Shanghai Escugen Biotechnol Co Ltd, Shanghai, Peoples R China
[19] Shanghai Escugen Biotechnol Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13132
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/ metastatic solid tumors
    Ma, Fei
    Qiu, Fuming
    Tong, Zhongsheng
    Wang, Jiani
    Tan, Yinuo
    Bai, Rui
    Zhou, Qing
    Xing, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
    Ma, F.
    Qiu, F.
    Tong, Z.
    Wang, J.
    Shi, Y.
    Li, L.
    Yu, G.
    Shi, H.
    Wu, X.
    Liu, A.
    Zhang, Y.
    Wang, H.
    Cheng, Y.
    Yang, H.
    Li, H.
    Chang, J.
    Zhou, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S359 - S359
  • [3] Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
    Yeonjin Jeon
    Uiree Jo
    Jongmoo Hong
    Gyungyub Gong
    Hee Jin Lee
    BMC Cancer, 22
  • [4] Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
    Jeon, Yeonjin
    Jo, Uiree
    Hong, Jongmoo
    Gong, Gyungyub
    Lee, Hee Jin
    BMC CANCER, 2022, 22 (01)
  • [5] TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer
    Cortesi, Michela
    Zanoni, Michele
    Maltoni, Roberta
    Ravaioli, Sara
    Tumedei, Maria Maddalena
    Pirini, Francesca
    Bravaccini, Sara
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (07) : 593 - 602
  • [6] Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer
    Ma, F.
    Qiu, F.
    Tong, Z.
    Wang, J.
    Shi, Y.
    Zhang, Y.
    Yu, G.
    Shi, H.
    Wu, X.
    Liu, A.
    Zhang, Y.
    Wang, H.
    Cheng, Y.
    Yang, H.
    Li, H.
    Chang, J.
    Xing, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S361 - S362
  • [7] Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors
    Wang, Jiani
    Tong, Zhongsheng
    Tan, Yinuo
    Shi, Yehui
    Wu, Yun
    Zhou, Qing
    Xing, Xiaoyan
    Chen, Xiaomei
    Qiu, Fuming
    Ma, Fei
    CELL REPORTS MEDICINE, 2024, 5 (09)
  • [8] Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer
    Zhao, Jing
    Huang, Fengbo
    Xu, Xia
    Zhang, Yan
    Xing, Xiaoyan
    Huang, Jian
    Qiu, Fuming
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
    McNamara, Blair
    Greenman, Michelle
    Bellone, Stefania
    Santin, Luca A.
    Demirkiran, Cem
    Mutlu, Levent
    Hartwich, Tobias Max Philipp
    Yang-Hartwich, Yang
    Ratner, Elena
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2024, 189 : 16 - 23
  • [10] TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer (vol 26, pg 593, 2022)
    Cortesi, M.
    Zanoni, M.
    Maltoni, R.
    Ravaioli, S.
    Tumedei, M. M.
    Pirini, F.
    Bravaccini, S.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022,
12345